Artelo Biosciences

Yahoo Finance • 14 days ago

Artelo Biosciences GAAP EPS of $3.97

* Artelo Biosciences press release [https://seekingalpha.com/pr/20303587-artelo-biosciences-provides-business-update-and-reports-third-quarter-2025-financial-results] (ARTL [https://seekingalpha.com/symbol/ARTL]): Q3 GAAP EPS of $3.97.... Full story

Yahoo Finance • last month

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in... Full story

Yahoo Finance • 2 months ago

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,... Full story

Yahoo Finance • 2 months ago

Artelo Biosciences launches underwritten public offering to raise capital

Artelo Biosciences (NASDAQ:ARTL [https://seekingalpha.com/symbol/ARTL]) has commenced an underwritten public offering [https://seekingalpha.com/pr/20248127-artelo-biosciences-announces-proposed-underwritten-public-offering] of its common s... Full story

Yahoo Finance • 2 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,... Full story

Yahoo Finance • 3 months ago

Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms

SOLANA BEACH, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,... Full story

Yahoo Finance • 3 months ago

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,... Full story

Yahoo Finance • 3 months ago

Let's take a look at the stocks that are in motion in today's session.

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] TOP GAINERS TICKER CHANGE COMMENT CIGL [https://www.chartmill.com/stock/quote/CIGL/profile] 91.84% CON... Full story

Yahoo Finance • 3 months ago

Top stock movements in today's session.

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] GAINERS TICKER CHANGE COMMENT CIGL [ht... Full story

Yahoo Finance • 3 months ago

Which stocks are gapping on Thursday?

In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT CIGL [https://www.chartmill.com/stoc... Full story

Yahoo Finance • 3 months ago

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,... Full story

Yahoo Finance • 3 months ago

Top movers in Thursday's pre-market session

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT BRIA [https://www.chartmill.com/st... Full story

Yahoo Finance • 3 months ago

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,... Full story

Yahoo Finance • 3 months ago

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including+6.4% M... Full story

Yahoo Finance • 3 months ago

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Safety and Pharmacokinetic Data Support Dosing of ART26.12 in Fed or Fasted Conditions Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances ART26.12 Toward Multiple Ascending Dose Trial... Full story

Yahoo Finance • 4 months ago

Artelo Biosciences secures European patent protection for cancer drug

SOLANA BEACH, Calif. - Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company with a market capitalization of $5.7 million, has received a Notice of Allowance from the European Patent Office for its patent applicat... Full story

Yahoo Finance • 4 months ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Extends Patent Protection Through December 2041 ART27.13 is Currently under Evaluation in a Phase 2 Study for the Treatment of Cancer-Related Anorexia SOLANA BEACH, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Na... Full story

Yahoo Finance • 4 months ago

Artelo Biosciences stock rating reaffirmed at Buy by D. Boral Capital

Investing.com - D. Boral (OTC:BOALY) Capital has reiterated its Buy rating on Artelo Biosciences , Inc. (NASDAQ:ARTL) with a price target of $20.00, representing a 100% upside from the current price of $10.01. According to InvestingPro da... Full story

Yahoo Finance • 4 months ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Lead investor Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner CUBE selected to secure storage, staking, and active DeFi execution of Artelo’s digital asset treasury Artelo’s Board approv... Full story

Yahoo Finance • 4 months ago

Curious about the stocks that are showing activity after the closing bell on Monday?

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. [postmarket] AFTER HOURS GAINERS TICKER CHANGE... Full story